Article
Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice.
Cancer chemotherapy and pharmacology - 1 Sept 2008
Zerbe Laura K, Dwyer-Nield Lori D, Fritz Jason M, Redente Elizabeth F, Shroyer Robert J, Conklin Elizabeth, Kane Shawn, Tucker Chris, Eckhardt S Gail, Gustafson Daniel L, Iwata Kenneth K, Malkinson Alvin M
Abstract excerpt
PURPOSE: Erlotinib, a small molecule inhibitor of the tyrosine kinase (TK) domain of epidermal growth factor receptor (EGFR), increases survival of advanced non-small cell lung cancer patients who failed standard chemotherapy (Phase III study). We evaluated whether erlotinib is also effective at an early stage of primary lung tumorigenesis in a carcinogen-induced lung tumor model in mice. METHODS: Sixteen weeks...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.